Categories U.S. Markets News

Accenture chief executive Pierre Nanterme resigns on health grounds

Accenture’s (ACN) Chairman and Chief Executive Officer Pierre Nanterme resigned with immediate effect on health grounds. The company appointed CFO David Rowland as the interim CEO and named KC McClure, who has been the head of Accenture’s finance operations, as CFO. Nanterme will continue at Accenture as an advisor to CEO.

Accenture CEO Pierre Nanterme resigns
Pierre Nanterme, Advisor to CEO               Image Courtesy: Accenture

Nanterme, who had served 36 years in Accenture, became the CEO of the company in early 2011 and Chairman in February 2013. During his eight-year tenure as CEO, he had significant involvement in moving Accenture’s focus to high-growth areas in the New – digital, cloud and security-related services.

In July 2016, Nanterme announced that he had undergone surgery after diagnosed with colon cancer and is moving to the next phase of the treatment.

 

 

David Rowland, Interim CEO, Accenture
David Rowland, Interim CEO                        Image Courtesy: Accenture

The newly appointed Interim CEO David Rowland served as the finance chief of the New York-based firm from July 2013. He also joins the Board as one of the directors. The Board also named Marge Magner as the non-executive chair.

“I know that David’s significant involvement in developing and delivering our growth strategy to rotate our business to new, high-growth areas of digital, cloud and security — and his tenure as a highly respected senior leader and developer of talent — will make this transition seamless,” said Pierre Nanterme.

Accenture’s shares have dropped 8% in the last 12 months and the stock opened in the red on Friday and continued to trade in the negative territory during the first hour of the trading session.

Accenture tops Q1 estimates; updates full-year outlook

 

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

 

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top